Jared Weiss, MD, discusses the efficacy results of the ongoing phase 1/2 KRYSTAL-1 trial in KRAS G12C–mutated colorectal cancer.
Jared Weiss, MD, associate professor of medicine, Division of Oncology, Department of Medicine, University of North Carolina (UNC) School of Medicine, associate director of finance, UNC Lineberger Clinical Protocol Office, UNC Lineberger Comprehensive Cancer Center, discusses the efficacy results of the ongoing phase 1/2 KRYSTAL-1 trial (NCT03785249) in KRAS G12C–mutated colorectal cancer (CRC).
During the 2021 ESMO Congress, findings from the KRYSTAL-1 trial, which evaluated adagrasib as monotherapy and in combination with cetuximab (Erbitux) in patients with KRAS G12C–mutated CRC, were presented.
Among 45 evaluable patients, single-agent adagrasib elicited a response rate of 22%, including 1 unconfirmed partial response (PR), Weiss says. The disease control rate (DCR) was 87%, the median duration of response (DOR) was 4.2 months, the median time to response was 1.4 months, and the median progression-free survival (PFS) was 5.6 months.
Among 28 evaluable patients, adagrasib in combination with cetuximab elicited a 43% response rate, including 2 unconfirmed PRs. The DCR was 100%, and the median time to response was 1.3 months, Weiss explains. DOR and PFS data were immature at the time of the data cutoff, but 71% of patients remained on treatment.
No apparent association between response rate and co-mutational status was observed with adagrasib monotherapy or in combination with cetuximab, Weiss concludes.